Sign In
Buy BBIO
$63.88
-1.48 (-2.26%)
At Close: Jun 02, 2026
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO
04:12am, Friday, 12'th Dec 2025
Frontier Capital Management Co. LLC lowered its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 30.4% during the undefined quarter, according to the company in its most recent disclosure with the
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle's disappointing earnings after the bell yesterday. The Federal Reserve's 25-basis-p
Federated Hermes Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO
04:56am, Thursday, 11'th Dec 2025
Federated Hermes Inc. bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exc
Edgestream Partners L.P. Makes New $1.92 Million Investment in BridgeBio Pharma, Inc. $BBIO
04:10am, Saturday, 06'th Dec 2025
Edgestream Partners L.P. purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the undefined quarter, according to the company in its most recent disclosure with the Securities a
American Century Companies Inc. Buys 62,646 Shares of BridgeBio Pharma, Inc. $BBIO
04:26am, Saturday, 29'th Nov 2025
American Century Companies Inc. raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 6.1% in the undefined quarter, according to its most recent disclosure with the SEC. The firm own
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of “Moderate Buy” by Analysts
02:12am, Thursday, 27'th Nov 2025
Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-one ratings firms that are currently covering the firm, Marketbeat r
BridgeBio to Participate in December Investor Conferences
07:30am, Tuesday, 25'th Nov 2025
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
Biotech Stock Could Turn 4-Year Peak Into Records
03:29pm, Monday, 24'th Nov 2025
BridgeBio Pharma Inc (NASDAQ:BBIO) stock is up 3.3% to trade at $70.36 at last check, and earlier hit a fresh four-year high $70.60 on a bounce off its 20-day moving average.
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes
07:04am, Sunday, 23'rd Nov 2025
BridgeBio has surged 90% since April 2025, driven by major clinical trial successes and robust commercial execution. BBIO's BBP-418 and Encaleret trials both exceeded expectations, each targeting bill
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 19'th Nov 2025
PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
08:21pm, Monday, 10'th Nov 2025
BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wad
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
10:41am, Saturday, 08'th Nov 2025
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared t
National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry
01:00pm, Friday, 07'th Nov 2025
Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enfor
Teacher Retirement System of Texas Grows Position in BridgeBio Pharma, Inc. $BBIO
03:45am, Wednesday, 05'th Nov 2025
Teacher Retirement System of Texas grew its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 8.3% during the undefined quarter, according to the company in its most recent filing with the Securities
BridgeBio to Participate in November Investor Conferences
07:30am, Tuesday, 04'th Nov 2025
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
